NCT07213583Active, not recruitingPhase 2
Study of Re-Treatment With ALXN2220 in Patients With ATTR-CM
A Phase 2, Single Arm, Multicenter Study to Evaluate the Pharmacodynamics and Safety of Re-Treatment With ALXN2220 in Patients With Transthyretin Amyloid Cardiomyopathy
Source: ClinicalTrials.gov · Last updated 7 Oct 2026
Brief summary (registry, in English)
This is a Phase 2, single-arm, multicenter study to evaluate the pharmacodynamics and safety of re-treatment with ALXN2220 in previous participants of Study NI006-101.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (estimated)
- First submitted
- 15 Sept 2025
- Start date
- 28 Aug 2025
- Primary completion date
- 31 Oct 2026
- Lead sponsor
- Neurimmune AG
- Diseases
- Amyloidosis
- NCT number
- NCT07213583
- EU CT number
- 2025-520506-35-00
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 35
- From 28 Aug 2025 to the primary completion date, 31 Oct 2026
- 6 sites in 4 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Suspected or known intolerance/allergy to proteins or any components of the study drug
- Any new or uncontrolled condition after completion of Study NI006-101 that could make the participant unsuitable for participation in this study
Other
- Treatment or study discontinuation in Study NI006-101 due to a treatment-related adverse event that was serious, severe or life-threatening (on Common terminology criteria for adverse events (CTCAE) scale)
Who the study is looking for
- Must have received at least one dose of ALXN2220 in Study NI006-101
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Universitätsklinikum Heidelberg Coordinator of this site? Confirm its status | Heidelberg | Germany | Unknown status |
| Hospital Universitario Puerta de Hierro - Majadahonda Coordinator of this site? Confirm its status | Majadahonda | Spain | Unknown status |
| Hopital Henri Mondor Coordinator of this site? Confirm its status | Créteil | France | Unknown status |
| CHU de Rennes - Hôpital Pontchaillou Coordinator of this site? Confirm its status | Rennes | France | Unknown status |
| Chu Toulouse Hopital Rangueil Coordinator of this site? Confirm its status | Toulouse | France | Unknown status |
| University Medical Center Groningen Coordinator of this site? Confirm its status | Groningen | Netherlands | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.